Bristol-Myers Squibb Company

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +40

Bristol Myers Squibb stock broadens AI strategy with Pathos deal

AI partnership New AI features AI-generated analysis

🀝 Bristol Myers Squibb partners with Pathos AI to integrate artificial intelligence and patient data into its neuroscience research strategy.

πŸ’° Pathos will license a de-identified dataset of hundreds of thousands of patients for five years at a cost of $55 million.

πŸ”’ BMS secures three-year exclusive rights to the Pathos Foundry platform specifically for its neuroscience development programs.

🧠 The collaboration focuses on improving disease understanding, patient selection, and clinical trial design for Alzheimer's and other neurological conditions.

πŸ’Έ Bristol Myers Squibb led a $237 million Series E financing round for Pathos AI, valuing the partner at approximately $3 billion.

🧬 The funded capital will advance four clinical assets, including JSKN016, a TROP2/HER3 bispecific antibody-drug conjugate.

Bullish Signals
  • Bristol Myers Squibb expands its AI and data capabilities in neuroscience through a strategic collaboration with Pathos AI.
  • The company secured three-year exclusive rights to the Pathos Foundry platform specifically for its neuroscience portfolio.
  • BMS is investing $55 million to license a large-scale de-identified dataset covering hundreds of thousands of patients for research.
Full Analysis
Bristol Myers Squibb (BMY) has expanded its artificial intelligence and data strategy in neuroscience through a new collaboration with Pathos AI. The partnership combines Pathos's AI capabilities, longitudinal patient data, and BMS's drug development expertise specifically to support Alzheimer's research and other neurological programs. Under the terms of the agreement, Pathos will license access to a de-identified dataset covering hundreds of thousands of patients for five years at a cost of $55 million. This arrangement grants Bristol Myers Squibb non-exclusive strategic access to the Pathos Foundry platform across its broader R&D portfolio, while securing three-year exclusive rights within the neuroscience sector. The collaboration aims to improve disease understanding, patient selection, and clinical trial design without providing immediate clinical efficacy data or a launch timetable. Additionally, BMY led Pathos AI's $237 million Series E financing round, valuing the company at approximately $3 billion, which will support the advancement of four clinical assets including the JSKN016 antibody-drug conjugate.